Disorders of bone remodeling

Annual Review of Pathology: Mechanisms of Disease

Volumn 6, Issue , 2011, Pages 121-145

  Feng, Xu ^a   McDonald, Jay M ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

osteopetrosis; osteoporosis; Paget's disease; renal osteodystrophy; rickets

Indexed keywords

PARATHYROID HORMONE; REACTIVE OXYGEN METABOLITE;

ALBERS SCHOENBERG DISEASE; ARTICLE; BONE DISEASE; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CORTICOSTEROID INDUCED OSTEOPOROSIS; GENETIC ASSOCIATION; HUMAN; IMMOBILIZATION INDUCED OSTEOPOROSIS; NONHUMAN; OSTEOPOROSIS; PAGET BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; RICKETS; SECONDARY OSTEOPOROSIS;

ANIMALS; BONE DISEASES; BONE REMODELING; HUMANS;

EID: 79751499788     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011110-130203     Document Type: Article

References (157)

1. Robey PG, Boskey AL. 2008. The composition of bone. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. ed. CJ Rosen, pp. 32-38. Washington, DC: Am. Soc. Bone Miner. Res.
2. McGowen JA, Raisz LG, Noonan AS, Elderkin AL. 2004. The frequency of bone diseases. In Bone Health and Osteoporosis: A Report of the Surgeon General, pp. 69-87. Rockville,MD: US Dep. Health Hum. Serv.
3. Parfitt AM. 1994. Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J. Cell Biochem. 55:273-86 (Pubitemid 24218802)
4. Seeman E. 2009. Bone modeling and remodeling. Crit. Rev. Eukaryot. Gene Expr. 19:219-33
5. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. 2001. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblasticmarkers. J. Bone Miner. Res. 16:1575-82 (Pubitemid 32786425)
6. Parfitt AM. 2001. The bone remodeling compartment: a circulatory function for bone lining cells. J. Bone Miner. Res. 16:1583-85 (Pubitemid 32786426)
7. Bonewald LF. 2007. Osteocytes as dynamic multifunctional cells. Ann. N.Y. Acad. Sci. 1116:281-90 (Pubitemid 350274320)
8. Santos A, Bakker AD, Klein-Nulend J. 2009. The role of osteocytes in bone mechanotransduction. Osteoporos. Int. 20:1027-31
9. Teitelbaum SL. 2000. Bone resorption by osteoclasts. Science 289:1504-8
10. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-42 (Pubitemid 40852708)
11. Ross FP, Teitelbaum SL. 2001. Osteoclast biology. In Osteoporosis, ed. R Marcus, D Feldman, J Kelsey, pp. 73-106. San Diego: Academic
12. Ducy P, Schinke T, Karsenty G. 2000. The osteoblast: a sophisticated fibroblast under central surveillance. Science 289:1501-4
13. Kuznetsov SA, MankaniMH, Gronthos S, Satomura K, Bianco P, Robey PG. 2001. Circulating skeletal stem cells. J. Cell Biol. 153:1133-40
14. Eghbali-Fatourechi G, Lamsam J, Fraser D,Nagel D, Riggs BL, Khosla S. 2005. Circulating osteoblastlineage cells in humans. N. Engl. J. Med. 352:1959-66
15. Modder UI, Khosla S. 2008. Skeletal stem/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. J. Cell Biochem. 103:393-400 (Pubitemid 351171911)
16. Parfitt AM. 2008. Skeletal heterogeneity and the purposes of bone remodeling: implications for the understanding of osteoporosis. In Osteoporosis, ed. RMarcus, D Feldman, DA Nelson, CJ Rosen, pp. 71-92. San Diego: Elsevier
17. Martin TJ, Seeman E. 2007. New mechanisms and targets in the treatment of bone fragility. Clin. Sci. (Lond.) 112:77-91 (Pubitemid 46120088)
18. Parfitt AM. 2002. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 30:5-7 (Pubitemid 34044294)
19. Andersen TL, Sondergaard TE, Skorzynska KE, Dagnaes-Hansen F, Plesner TL, et al. 2009. A physical mechanism for coupling bone resorption and formation in adult human bone.Am. J. Pathol. 174:239-47
20. Raisz LG. 1988. Hormonal regulation of bone growth and remodelling. Ciba Found. Symp. 136:226-38
21. Mohan S, Baylink DJ. 1996. Insulin-like growth factor system components and the coupling of bone formation to resorption. Horm. Res. 45(Suppl. 1):59-62 (Pubitemid 26188661)
22. Mundy GR. 1991. The effects of TGF-âon bone. Ciba Found. Symp. 157:137-43
23. Tang Y, Wu X, LeiW, Pang L,Wan C, et al. 2009. TGF-â1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15:757-65
24. Falany ML, Thames AM III, McDonald JM, Blair HC, McKenna MA, et al. 2001. Osteoclasts secrete the chemotactic cytokine mim-1. Biochem. Biophys. Res. Commun. 281:180-85 (Pubitemid 32924416)
25. Martin T, Gooi JH, Sims NA. 2009. Molecular mechanisms in coupling of bone formation to resorption. Crit. Rev. Eukaryot. Gene Expr. 19:73-88
26. Matsuo K, Irie N. 2008. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 473:201-9
27. Andersen TL, Soe K, Sondergaard TE, Plesner T, Delaisse JM. 2009. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br. J. Haematol. 48:551-61
28. Natl. Inst. Health Consens. Dev. Panel. 2001. Osteoporosis prevention, diagnosis, and therapy. J. Am. Med. Assoc. 285:785-95
29. Marcus R, Bouxsein M. 2008. The nature of osteoporosis. In Osteoporosis, ed. R Marcus, D Feldman, DA Nelson, CJ Rosen, pp. 27-36. San Diego: Academic
30. Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, et al. 1982. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J. Clin. Investig. 70:716-23 (Pubitemid 12038087)
31. Riggs BL, Khosla S, Melton LJ. 2001. The type I/type II model for involutional osteoporosis. In Osteoporosis, ed. R Marcus, D Feldman, J Kelsey, pp. 49-58. San Diego: Academic
32. Albright F, Smith PH, Richardson AM. 1941. Postmenopausal osteoporosis. J.Am.Med. Assoc. 116:2465-74
33. Heaney RP, Recker RR, Saville PD. 1978. Menopausal changes in bone remodeling. J. Lab. Clin. Med. 92:964-70 (Pubitemid 9090267)
34. Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'FallonWM, Riggs BL. 1990. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J. Bone Miner. Res. 5:311-9 (Pubitemid 20276829)
35. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. 1996. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11:337-49 (Pubitemid 26076383)
36. Raisz LG. 2005. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Investig. 115:3318-25 (Pubitemid 43121814)
37. Horowitz MC. 1993. Cytokines and estrogen in bone: antiosteoporotic effects. Science 260:626-27 (Pubitemid 23167587)
38. Manolagas SC, Jilka RL. 1995. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332:305-11
39. Jilka RL. 1998. Cytokines, bone remodeling, and estrogen deficiency-a 1998 update. Bone 23:75-81 (Pubitemid 28379866)
40. Pacifici R. 1998. Cytokines, estrogen, and postmenopausal osteoporosis-the second decade. Endocrinol. 139:2659-61
41. Pacifici R, Rifas L, Teitelbaum S, Slatopolsky E,Miller R, et al. 1987. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc. Natl. Acad. Sci. USA 84:4616-20 (Pubitemid 17097860)
42. Pacifici R, Brown C, Puscheck E, Friedrich E, Slatopolsky E, et al. 1991. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. USA 88:5134-38 (Pubitemid 21914698)
43. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, et al. 1988. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241:81-83
44. Roggia C, Gao Y, Cenci S,Weitzmann MN, Toraldo G, et al. 2001. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98:13960-65 (Pubitemid 33116006)
45. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, et al. 1992. 17 â-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J. Clin. Investig. 89:883-91
46. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, et al. 1992. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91
47. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. 2000. Tumor necrosis factor áinduces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275:4858-64 (Pubitemid 30108878)
48. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, et al. 2000. Tumor necrosis factor ástimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-85 (Pubitemid 30060917)
49. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. 2000. TNF-áinduces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Investig. 106:1481-88 (Pubitemid 32038586)
50. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L. 2004. RANK signaling is not required for TNFá-mediated increase inCD11hi osteoclast precursors but is essential formature osteoclast formation in TNFá-mediated inflammatory arthritis. J. Bone Miner. Res. 19:207-13 (Pubitemid 38116734)
51. LaceyDL, Timms E, TanHL, KelleyMJ, Dunstan CR, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-76 (Pubitemid 28180851)
52. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-602
53. Anderson DM,Maraskovsky E, BillingsleyWL, Dougall WC, TometskoME, et al. 1997. A homologue of theTNFreceptor and its ligand enhanceT-cell growth and dendritic-cell function. Nature 390:175-79 (Pubitemid 27507987)
54. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-94 (Pubitemid 27415705)
55. Bucay N, Sarosi I, DunstanCR, Morony S, Tarpley J, et al. 1998. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12:1260-68 (Pubitemid 28213402)
56. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-19 (Pubitemid 27199902)
57. Wong BR, Josien R, Lee SY, Sauter B, Li HL, et al. 1997. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186:2075-80 (Pubitemid 28013694)
58. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. 1999. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162:2562-68 (Pubitemid 29309274)
59. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, et al. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-23
60. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189:1025-31 (Pubitemid 29169819)
61. DougallWC,GlaccumM,Charrier K, Rohrbach K, Brasel K, et al. 1999.RANKis essential for osteoclast and lymph node development. Genes Dev. 13:2412-24 (Pubitemid 29453612)
62. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, et al. 2000. The osteoclast differentiation factor osteoprotegerin ligand is essential for mammary gland development. Cell 103:41-50
63. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, et al. 2009. Central control of fever and female body temperature by RANKL/RANK. Nature 462:505-9
64. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-57 (Pubitemid 30649812)
65. Takayanagi H, Kim S,Matsuo K, Suzuki H, Suzuki T, et al. 2002. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-â. Nature 416:744-49 (Pubitemid 34429151)
66. Feng X. 2005. Regulatory roles and molecular signaling of TNF family members in osteoclasts. Gene 350:1-13
67. Williams JP, McDonald JM, McKenna MA, Jordan SE, Radding W, Blair HC. 1997. Differential effects of tamoxifen-like compounds on osteoclastic bone degradation, H+-ATPase activity, calmodulindependent cyclic nucleotide phosphodiesterase activity, and calmodulin binding. J. Cell Biochem. 66:358-69 (Pubitemid 27332869)
68. Williams JP, Micoli K, McDonald JM. 2010. Calmodulin-an often-ignored signal in osteoclasts. Ann. N.Y. Acad. Sci. 1192:358-64
69. Zhang L, Feng X, McDonald JM. 2003. The role of calmodulin in the regulation of osteoclastogenesis. Endocrinol. 144:4536-43 (Pubitemid 37204853)
70. Saika M, Inoue D, Kido S, Matsumoto T. 2001. 17â-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor á. Endocrinology 142:2205-12 (Pubitemid 32473073)
71. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. 2003. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Investig. 111:1221-30 (Pubitemid 36519939)
72. Shevde NK, Bendixen AC, Dienger KM, Pike JW. 2000. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97:7829-34 (Pubitemid 30460733)
73. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. 2001. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-êB ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276:8836-40
74. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, et al. 2000. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-á. J. Clin. Investig. 106:1229-37
75. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, et al. 2007. Estrogen prevents bone loss via estrogen receptor áand induction of Fas ligand in osteoclasts. Cell 130:811-23 (Pubitemid 47332572)
76. Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. 2003. Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology 144:5545-55 (Pubitemid 37476084)
77. Manolagas SC. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21:115-37 (Pubitemid 32275592)
78. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. 1996. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-â. Nat. Med. 2:1132-36
79. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, et al. 2006. FSH directly regulates bone mass. Cell 125:247-60
80. Stefanick ML. 2005. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am. J. Med. 118(Suppl. 12B):64-73
81. Prince R, Muchmore DB, Siris ES. 2008. Estrogen analogues: selective estrogen receptor modulators and phytoestrogens. In Osteoporosis, ed. RMarcus, D Feldman, DA Nelson, CJ Rosen, pp. 1705-23. San Diego: Academic
82. Miller P. 2008. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In Osteoporosis, ed. R Marcus, D Feldman, DA Nelson, CJ Rosen, pp. 1725-42. San Diego: Academic
83. Gruber HE, Ivey JL, Baylink DJ, Matthews M, NelpWB, et al. 1984. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295-303 (Pubitemid 14135344)
84. Lewiecki EM. 2009. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J. Womens Health 18:1615-26
85. Miller PD. 2009. Denosumab: anti-RANKL antibody. Curr. Osteoporos. Rep. 7:18-22
86. Girotra M, Rubin MR, Bilezikian JP. 2006. The use of parathyroid hormone in the treatment of osteoporosis. Rev. Endocr. Metab Disord. 7:113-21 (Pubitemid 46049523)
87. Khosla S, Riggs BL. 2005. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol.Metab. Clin. N. Am. 34:1015-30, xi (Pubitemid 41677410)
88. Balaban RS, Nemoto S, Finkel T. 2005. Mitochondria, oxidants, and aging. Cell 120:483-95 (Pubitemid 40269763)
89. Finkel T, Holbrook NJ. 2000. Oxidants, oxidative stress and the biology of ageing. Nature 408:239-47
90. Giorgio M, Trinei M, Migliaccio E, Pelicci PG. 2007. Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? Nat. Rev. Mol. Cell Biol. 8:722-28 (Pubitemid 47312827)
91. Baron R, Rawadi G. 2007. Wnt signaling and the regulation of bone mass. Curr. Osteoporos. Rep. 5:73-80 (Pubitemid 46954745)
92. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC. 2007. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting â-catenin from T cell factor-to forkhead box O-mediated transcription. J. Biol. Chem. 282:27298-305 (Pubitemid 47501978)
93. Manolagas SC. 2010. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31:266-300
94. Zayzafoon M, Fulzele K, McDonald JM. 2005. Calmodulin and calmodulin-dependent kinase II á regulate osteoblast differentiation by controlling c-fos expression. J. Biol. Chem. 280:7049-59 (Pubitemid 40341261)
95. YeoH,McDonald JM, Zayzafoon M. 2006. NFATcl: A novel anabolic therapeutic target for osteoporosis. Ann. N.Y. Acad. Sci. 1068:564-67 (Pubitemid 43824183)
96. Yeo H, Beck LH, McDonald JM, Zayzafoon M. 2007. Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone 40:1502-16 (Pubitemid 46766648)
97. Giustina A, Mazziotti G, Canalis E. 2008. Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29:535-59
98. DiGirolamo DJ, Mukherjee A, Fulzele K, Gan Y, Cao X, et al. 2007. Mode of growth hormone action in osteoblasts. J. Biol. Chem. 282:31666-74 (Pubitemid 350044902)
99. Gevers EF, Loveridge N, Robinson IC. 2002. Bone marrow adipocytes: a neglected target tissue for growth hormone. Endocrinol. 143:4065-73 (Pubitemid 35244386)
100. Barnard R,NgKW, Martin TJ,WatersMJ. 1991. Growth hormone (GH) receptors in clonal osteoblastlike cells mediate a mitogenic response to GH. Endocrinology 128:1459-64
101. KassemM, BlumW,Ristelli J, Mosekilde L, Eriksen EF. 1993. Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro. Calcif. Tissue Int. 52:222-26 (Pubitemid 23090716)
102. Li H, Bartold PM, Zhang CZ, Clarkson RW, Young WG, Waters MJ. 1998. Growth hormone and insulin-like growth factor I induce bone morphogenetic proteins 2 and 4: a mediator role in bone and tooth formation? Endocrinology 139:3855-62 (Pubitemid 28512268)
103. Rivadeneira F, Houwing-Duistermaat JJ, Vaessen N, Vergeer-Drop JM, Hofman A, et al. 2003. Association between an insulin-like growth factor I gene promoter polymorphism and bone mineral density in the elderly: the Rotterdam Study. J. Clin. Endocrinol. Metab. 88:3878-84 (Pubitemid 37034542)
104. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, et al. 1998. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J. Clin. Endocrinol. Metab. 83:4257-62 (Pubitemid 29100118)
105. Riggs BL. 2003. Role of the vitamin D-endocrine system in the pathophysiology of postmenopausal osteoporosis. J. Cell Biochem. 88:209-15 (Pubitemid 36119888)
106. Kalu DN, Orhii PB. 1999. Calcium absorption and bone loss in ovariectomized rats fed varying levels of dietary calcium. Calcif. Tissue Int. 65:73-77 (Pubitemid 29293531)
107. McCarthy TL, Centrella M, Canalis E. 1990. Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures. J. Biol. Chem. 265:15353-56
108. Riggs BL, Khosla S, Melton LJ, III. 2002. Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23:279-302 (Pubitemid 34651948)
109. Khosla S, Melton LJ III, Atkinson EJ, O'FallonWM, Klee GG, Riggs BL. 1998. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83:2266-74 (Pubitemid 28503012)
110. Khosla S. 2010. Update in male osteoporosis. J. Clin. Endocrinol. Metab. 95:3-10
111. Adler RA, Curtis J, Weinstein RS, Saag KG. 2008. Glucocorticoid-induced osteoporosis. In Osteoporosis, ed. R Marcus, D Feldman, DA Nelson, CJ Rosen, pp. 1135-66. San Diego: Academic
112. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. 2000. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15:993-1000 (Pubitemid 30350061)
113. Liu ZJ, Zhuge Y, Velazquez OC. 2009. Trafficking and differentiation of mesenchymal stem cells. J. Cell. Biochem. 106:984-91
114. Vande Berg BC,Malghem J, Lecouvet FE, Devogelaer JP, Maldague B, Houssiau FA. 1999. Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum. 42:1405-11 (Pubitemid 30265598)
115. Canalis E. 1983. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. Endocrinol. 112:931-39
116. Peretz A, Praet JP, Bosson D, Rozenberg S, Bourdoux P. 1989. Serum osteocalcin in the assessment of corticosteroid induced osteoporosis. Effect of long and short term corticosteroid treatment. J. Rheumatol. 16:363-67 (Pubitemid 19104577)
117. YaoW, Cheng Z, Pham A, Busse C, Zimmermann EA, et al. 2008. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum. 58:3485-97
118. WeinsteinRS, JilkaRL, ParfittAM,Manolagas SC. 1998. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Investig. 102:274-82 (Pubitemid 28335186)
119. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, et al. 1999. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinol. 140:4382-89 (Pubitemid 30666099)
120. Jia D, O'Brien CA, Stewart SA, Manolagas SC, Weinstein RS. 2006. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinol. 147:5592-99 (Pubitemid 44833476)
121. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, et al. 2006. Glucocorticoids suppress bone formation via the osteoclast. J. Clin. Investig. 116:2152-60 (Pubitemid 44162324)
122. KimHJ, Zhao H, KitauraH, Bhattacharyya S, Brewer JA, et al. 2007. Glucocorticoids and the osteoclast. Ann. N.Y. Acad. Sci. 1116:335-39 (Pubitemid 350274339)
123. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. 2007. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18:1319-28 (Pubitemid 47389469)
124. Saag KG, Shane E, Boonen S, Marin F, Donley DW, et al. 2007. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357:2028-39 (Pubitemid 350106710)
125. Takata S, Yasui N. 2001. Disuse osteoporosis. J. Med. Investig. 48:147-56
126. Zayzafoon M, Meyers VE,McDonald JM. 2005. Microgravity: the immune response and bone. Immunol. Rev. 208:267-80 (Pubitemid 41746398)
127. Collet P, Uebelhart D, Vico L, Moro L, Hartmann D, et al. 1997. Effects of 1-and 6-month spaceflight on bone mass and biochemistry in two humans. Bone 20:547-51 (Pubitemid 27270469)
128. Lang T, LeBlanc A, Evans H, Lu Y, Genant H, Yu A. 2004. Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J. Bone Miner. Res. 19:1006-12 (Pubitemid 41103458)
129. Smith SM, Nillen JL, LeBlanc A, Lipton A, Demers LM, et al. 1998. Collagen cross-link excretion during space flight and bed rest. J. Clin. Endocrinol. Metab. 83:3584-91 (Pubitemid 28500894)
130. Smith SM, Wastney ME, O'Brien KO, Morukov BV, Larina IM, et al. 2005. Bone markers, calcium metabolism, and calcium kinetics during extended-duration space flight on the Mir space station. J. Bone Miner. Res. 20:208-18
131. You J, Yellowley CE, Donahue HJ, Zhang Y, Chen Q, Jacobs CR. 2000. Substrate deformation levels associated with routine physical activity are less stimulatory to bone cells relative to loading-induced oscillatory fluid flow. J. Biomech. Eng. 122:387-93
132. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, et al. 2007. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 5:464-75 (Pubitemid 46825494)
133. Papachroni KK, Karatzas DN, Papavassiliou KA, Basdra EK, Papavassiliou AG. 2009. Mechanotransduction in osteoblast regulation and bone disease. Trends Mol. Med. 15:208-16
134. Rubin J, Fan X, Biskobing DM, Taylor WR, Rubin CT. 1999. Osteoclastogenesis is repressed by mechanical strain in an in vitro model. J. Orthop. Res. 17:639-45
135. Rubin J, Murphy TC, Fan X, Goldschmidt M, Taylor WR. 2002. Activation of extracellular signalregulated kinase is involved in mechanical strain inhibition of RANKL expression in bone stromal cells. J. Bone Miner. Res. 17:1452-60 (Pubitemid 34803829)
136. WiltinkA,NijweidePJ, Scheenen WJ,YpeyDL, Van DuijnB. 1995. Cell membrane stretch in osteoclasts triggers a self-reinforcing Ca2+ entry pathway. Pflüg. Arch. 429:663-71
137. Saxena R, Pan G, Dohm EK, McDonald JM. 2010. Modeled microgravity and hindlimb unloading sensitize osteoclast precursors to RANKL-mediated osteoclastogenesis. J. Bone Miner. Metab. In press
138. Rubin J, Rubin C, Jacobs CR. 2006. Molecular pathways mediating mechanical signaling in bone. Gene 367:1-16 (Pubitemid 43286736)
139. Chen JH, Liu C, You L, Simmons CA. 2010. Boning up on Wolff 's Law: mechanical regulation of the cells that make and maintain bone. J. Biomech. 43:108-18
140. Phillips JA, Almeida EA, Hill EL, Aguirre JI, Rivera MF, et al. 2008. Role for â1 integrins in cortical osteocytes during acute musculoskeletal disuse. Matrix Biol. 27:609-18
141. Davidson RM, Tatakis DW, Auerbach AL. 1990. Multiple forms of mechanosensitive ion channels in osteoblast-like cells. Pflüg. Arch. 416:646-51 (Pubitemid 20294181)
142. Meyers VE, Zayzafoon M, Gonda SR, Gathings WE, McDonald JM. 2004. Modeled microgravity disrupts collagen I/integrin signaling during osteoblastic differentiation of human mesenchymal stem cells. J. Cell Biochem. 93:697-707 (Pubitemid 44264166)
143. Meyers VE, Zayzafoon M, Douglas JT,McDonald JM. 2005. RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity. J. Bone Miner. Res. 20:1858-66 (Pubitemid 41361888)
144. Bikle DD, Morey-Holton ER, Doty SB, Currier PA, Tanner SJ, Halloran BP. 1994. Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage. J. Bone Miner. Res. 9:1777-87 (Pubitemid 24341199)
145. Turner RT, Evans GL, Lotinun S, Lapke PD, Iwaniec UT, Morey-Holton E. 2007. Dose-response effects of intermittent PTH on cancellous bone in hindlimb unloaded rats. J. Bone Miner. Res. 22:64-71 (Pubitemid 46032598)
146. Block GA, Cunningham J. 2006. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. In Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD, ed. K Olgaard, pp. 77-92. New York: Natl. Kidney Found.
147. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, et al. 2006. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69:1945-53 (Pubitemid 43924257)
148. Malluche HH, Monier-Faugere MC, Herberth J. 2010. Bone disease after renal transplantation. Nat. Rev. Nephrol. 6:32-40
149. HruskaKA. 2008. Chronic kidney disease mineral bone disorder (CKD-MBD). In Primer on theMetabolic Bone Diseases and Disorders of Mineral Metabolism, ed. CJ Rosen, pp. 343-49. Washington, DC: Am. Soc. Bone Miner. Res.
150. Singer FR. 2009. Paget disease: when to treat and when not to treat. Nat. Rev. Rheumatol. 5:483-89
151. Siris ES, Feldman F. 1997. Natural history of untreated Paget's disease of the tibia. J. Bone Miner. Res. 12: 691-92 (Pubitemid 27155230)
152. Siris ES. 1995. Extensive personal experience: Paget's disease of bone. J. Clin. Endocrinol. Metab. 80:335-38
153. Michou L, Chamoux E, Couture J, Morissette J, Brown JP, Roux S. 2010. Gene expression profile in osteoclasts from patients with Paget's disease of bone. Bone 46:598-603
154. Tolar J, Teitelbaum SL, Orchard PJ. 2004. Osteopetrosis. N. Engl. J. Med. 351:2839-49
155. Stark Z, Savarirayan R. 2009. Osteopetrosis. Orphanet J. Rare. Dis. 4:5
156. Driessen GJ, Gerritsen EJ, Fischer A, Fasth A,Hop WC, et al. 2003. Long-term outcome of haematopoietic stem cell transplantation in autosomal recessive osteopetrosis: an EBMTreport. Bone Marrow Transplant. 32:657-63 (Pubitemid 37258621)
157. Lips P, van Schoor NM, Bravenboer N. 2008. Vitamin D-related disorders. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, ed. CJ Rosen, pp. 329-35. Washington, DC: Am. Soc. Bone Miner. Res.